SAN DIEGO, Aug. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the second quarter and six months ended June 30, 2007. Cadence reported a net loss for the second quarter of 2007 of $14.9 million, or $0.52 per share, compared to a net loss of $6.2 million, or $4.92 per share, in the second quarter of 2006. For the six months ended June 30, 2007, the company reported a net loss of $24.5 million, or $0.86 per share, compared to a net loss of $35.4 million, or $28.50 per share for the six months ended June 30, 2006.
As of June 30, 2007, Cadence held cash and cash equivalents of $66.9 million.
"We remain keenly focused on executing the development programs for our two Phase III product candidates, intravenous acetaminophen and Omigard(TM)," said Ted Schroeder, Cadence's President and Chief Executive Officer. "As a result, we are on track to meet our clinical development and pre-commercialization manufacturing objectives for both product candidates. In particular, we are pleased with the recent execution of a development and supply agreement for IV acetaminophen with Baxter Healthcare, a leading global contract manufacturer, which we believe will position us to meet the anticipated demand for this important product candidate upon commercialization and for several years thereafter."
Total operating expenses for the second quarter of 2007 were $15.7 million, compared to $6.6 million for the second quarter of 2006. The increase in operating expenses was primarily due to a $7.8 million increase in research and development expenses related to the company's ongoing Phase III clinical trials of Omigard and IV acetaminophen. In addition, the increased operating expenses were due to pre-commercialization manufacturing development activities for IV acetaminophen, increased personnel related costs due to the planned hiring of staff to support the company's clinical and regulatory efforts, and a $1.0 million increase in general and administrative expenses due to increases in labor related costs, costs related to operating as a public company, insurance costs and depreciation expense.
For the six months ended June 30, 2007, operating expenses were $26.0 million, compared to $35.9 million for the six months ended June 30, 2006. The decrease in operating expenses was primarily related to a one-time initial license fee of $25.3 million incurred by Cadence during the first quarter of 2006 in connection with the acquisition of rights to IV acetaminophen. This decrease was partially offset by a $12.6 million increase in costs during the first six months of 2007 related to the company's ongoing Phase III clinical trials of Omigard and IV acetaminophen, pre-commercialization manufacturing development activities for IV acetaminophen, personnel related costs due to the planned hiring of staff to support the company's clinical and regulatory efforts, and a $2.3 million increase in general and administrative expenses due to increases in stock-based compensation, labor related costs, costs related to operating as a public company, depreciation expense and insurance costs.
Recent Highlights and Developments
-- On July 26, 2007, Cadence announced that the FDA agreed with the
company's plan to increase enrollment in the ongoing Phase III clinical
trial of Omigard from 1,250 to 1,850 patients in order to maintain the
statistical power of the study in light of a re-analysis of data from
the initial Phase III clinical trial of Omigard. The company currently
anticipates completing enrollment of its new goal of 1,850 patients in
the second quarter of 2008 and, if the results are positive, submitting
a New Drug Application for Omigard in the first half of 2009.
-- Also in July 2007, Cadence signed a development and supply agreement
with Baxter Healthcare Corporation for the completion of
pre-commercialization manufacturing development activities and the
manufacture of commercial supplies of finished drug product for IV
-- In June 2007, the company completed enrollment of the original target
of 1,250 patients in the Omigard clinical trial two months ahead of
Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time
Cadence management will host a conference call on Tuesday, August 14, 2007 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results for the second quarter ended June 30, 2007. Interested investors may participate in the conference call by dialing (888) 802-2225 (domestic) or (913) 312-1268 (international). To access the webcast, please log on to the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, intravenous acetaminophen for the treatment of acute pain and fever, and Omigard (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.
Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding: the anticipated completion of the increased enrollment of patients in the ongoing Phase III clinical trial of Omigard; the potential for filing New Drug Applications, or NDAs, for Omigard and IV acetaminophen and the timing of any such filings; and the expected progress in achieving clinical and pre-commercialization manufacturing development objectives for both product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: the progress and results of the company's clinical trials of IV acetaminophen and Omigard, including any delays in commencing or completing enrollment; unexpected adverse side effects or inadequate therapeutic efficacy of IV acetaminophen or Omigard that could delay or prevent regulatory approval or commercialization, or that could result in recalls or product liability claims; the adequacy of the trial designs for Cadence's on-going Phase III clinical trials of Omigard and IV acetaminophen to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including NDAs; any failure by Cadence's contract manufacturers or suppliers to produce its product candidates in the required volumes on a timely basis, or to comply with applicable regulations; any uncured, material breaches of the agreements with, or termination or disruption of the company's relationships with, its contract manufacturers or suppliers; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for IV acetaminophen or Omigard; the scope and validity of patent protection for IV acetaminophen or Omigard; the company's ability to maintain patent protection for its product candidates and to commercialize its product candidates without infringing the patent rights of others; the market potential for pain, fever, local catheter site infections and other target markets, and the company's ability to compete; the potential to attract a strategic collaborator and terms of any related transaction; the company's ability to raise sufficient capital; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
Director, Investor Relations
Cadence Pharmaceuticals, Inc.
Porter Novelli Life Sciences
CADENCE PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED STATEMENTS OF OPERATIONS
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
development $12,754,991 $4,928,724 $20,996,795 $33,663,970
Marketing 466,354 220,783 768,537 316,541
administrative 2,435,940 1,430,631 4,263,532 1,967,980
expenses 15,657,285 6,580,138 26,028,864 35,948,491
operations (15,657,285) (6,580,138) (26,028,864) (35,948,491)
Other income, net 722,696 381,333 1,534,577 508,606
Net loss $(14,934,589) $(6,198,805) $(24,494,287) $(35,439,885)
Basic and diluted
net loss per
share(1) $(0.52) $(4.92) $(0.86) $(28.50)
Shares used to
compute basic and
diluted net loss
per share(1) 28,546,033 1,260,132 28,475,594 1,243,500
(1) As a result of the issuance of 6,900,000 shares of common stock in
the Company's initial public offering in the fourth quarter of 2006
and the conversion of the Company's preferred stock into 19,907,605
shares of common stock upon completion of the Company's initial
public offering, there is a lack of comparability in the basic and
diluted net loss per share amounts for the periods presented above.
CADENCE PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
June 30, December 31,
Cash and cash equivalents $66,922,662 $86,825,526
Restricted cash 1,981,849 347,849
Prepaid expenses and other
current assets 759,269 820,311
Total current assets 69,663,780 87,993,686
Property and equipment, net 4,716,313 3,558,618
Restricted cash 1,233,281 1,233,281
Other assets 444,832 536,042
Total assets $76,058,206 $93,321,627
Liabilities and Stockholders' Equity
Accounts payable $5,040,081 $2,073,726
Accrued liabilities 10,959,172 7,378,750
Current portion of long-term debt 2,687,790 2,338,010
Total current liabilities 18,687,043 11,790,486
Deferred rent 1,347,069 1,460,109
Long-term debt, less current portion 3,279,753 4,661,990
Other long-term liabilities 22,048 -
Total stockholders' equity 52,722,293 75,409,042
Total liabilities and stockholders'
equity $76,058,206 $93,321,627
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.